Two-year use of flash glucose monitoring is associated with sustained improvement of glycemic control and quality of life (FLARE-NL-6).
continuous glucose monitoring
diabetes mellitus
patient reported outcome measures
type 1
Journal
BMJ open diabetes research & care
ISSN: 2052-4897
Titre abrégé: BMJ Open Diabetes Res Care
Pays: England
ID NLM: 101641391
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
09
01
2021
accepted:
18
08
2021
entrez:
15
9
2021
pubmed:
16
9
2021
medline:
13
10
2021
Statut:
ppublish
Résumé
The FreeStyle Libre (FSL) is a flash glucose monitoring (FGM) system. The Flash Monitor Register in the Netherlands (FLARE-NL-4) study previously demonstrated the positive effects of FSL-FGM use during 1 year on glycemic control, quality of life and disease burden among persons with diabetes mellitus (DM). The present follow-up study assesses the effects of FSL-FGM after 2 years. Patients included in the FLARE-NL-4 study who continued FSL-FGM during the 1-year study period were invited to participate (n=687). Data were collected using questionnaires (the 12-Item Short Form Health Survey version 2 (SF-12 A total of 342 patients agreed to participate: mean age 48.0 (±15.6) years, 52% men and 79.5% with type 1 DM. HbA1c decreased from 60.7 (95% CI 59.1 to 62.3) mmol/mol before use of FSL-FGM to 57.3 (95% CI 55.8 to 58.8) mmol/mol after 1 year and 57.8 (95% CI 56.0 to 59.5) mmol/mol after 2 years. At the end of the 2-year follow-up period, 260 (76%) persons were still using the FSL-FGM and 82 (24%) had stopped. The main reason for stopping FSL-FGM was financial constraints (55%). Concerning the whole 2-year period, there was a significant decrease in HbA1c among persons who continued use of FSL-FGM (-3.5 mmol/mol, 95% CI -6.4 to -0.7), while HbA1c was unaltered compared with baseline among persons who stopped FSL-FGM (-2.4 mmol/mol, 95% CI -7.5 to 2.7): difference between groups 2.2 (95% CI -1.3 to 5.8) mmol/mol. After 2 years, persons who continued use of FSL-FGM had higher SF-12 mental component score and higher EQ-5D Dutch tariff score and felt less often anxious or depressed compared with persons who discontinued FSL-FGM. Although the considerable number of non-responders limits generalizability, this study suggests that persons who continue to use FSL-FGM for 2 years may experience sustained improvement in glycemic control and quality of life.
Identifiants
pubmed: 34521652
pii: 9/1/e002124
doi: 10.1136/bmjdrc-2021-002124
pmc: PMC8442047
pii:
doi:
Substances chimiques
Blood Glucose
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Diabetes Care. 2020 Sep;43(9):2153-2160
pubmed: 32669277
Diabetes Metab Syndr. 2020 Mar - Apr;14(2):65-69
pubmed: 31991294
Diabetes Res Clin Pract. 2021 Jul;177:108897
pubmed: 34098059
Diabetes Ther. 2019 Aug;10(4):1239-1248
pubmed: 31066017
BMJ Open Diabetes Res Care. 2020 Jun;8(1):
pubmed: 32487593
Diabetologia. 2019 Aug;62(8):1349-1356
pubmed: 31177314
Diabetes Ther. 2020 Jan;11(1):83-95
pubmed: 31673972
Health Policy. 1990 Dec;16(3):199-208
pubmed: 10109801
Exp Clin Endocrinol Diabetes. 2021 Mar;129(4):303-308
pubmed: 31185506
Nutrients. 2018 Jul 29;10(8):
pubmed: 30060632
Med Care. 1996 Mar;34(3):220-33
pubmed: 8628042
Diabetes Care. 2020 Feb;43(2):389-397
pubmed: 31843948
Diabetes Care. 2017 Jan;40(1):155-157
pubmed: 27872155
J Diabetes Complications. 2020 Jun;34(6):107559
pubmed: 32089428
BMJ Open Diabetes Res Care. 2019 Dec 9;7(1):e000809
pubmed: 31875133
Ned Tijdschr Geneeskd. 2005 Jul 9;149(28):1574-8
pubmed: 16038162
Int J Endocrinol. 2019 Nov 3;2019:4649303
pubmed: 31781209